Erik Manting - 10 May 2023 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role
Director
Signature
/s/ Thomas A. Fitzgerald, as Attorney-in-Fact
Issuer symbol
RNAZ
Transactions as of
10 May 2023
Net transactions value
$0
Form type
4
Filing time
10 May 2023, 18:13:03 UTC
Previous filing
22 Jun 2022
Next filing
19 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNAZ Stock Option (Right to Buy) Award $0 +9,500 $0.000000 9,500 10 May 2023 Common Stock 9,500 $0.2985 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 10, 2024 and (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.